论文部分内容阅读
目的:探讨阿托伐他汀治疗冠心病的临床疗效及其可能机制。方法:按照抽签法将170例冠心病患者分为对照组(n=85)及研究组(n=85),对照组予以常规治疗,研究组在对照组基础上使用阿托伐他汀治疗,比较两组治疗前后血清炎症因子[肿瘤坏死因子-α(TNF-α)、基质金属蛋白酶-9(MMP-9)、C反应蛋白(CRP)]水平、氧化应激水平[血清丙二醇(MDA)、超氧化物歧化酶(SOD)水平]、血管内皮功能[血清一氧化氮(NO)、内皮素-1(ET-1)水平]、血脂水平及心功能的变化。结果:治疗后,研究组患者血清TNF-α、MMP-9、CRP、MDA、ET-1、总胆固醇(TC)、甘油三脂(TG)、左心室舒张末期内径(LVEDD)、左心室收缩末期内径(LVESD)水平均显著低于对照组,而血清SOD、NO、高密度脂蛋白(HDL-C)左心室射血分数(LVEF)水平均显著高于对照组,差异有统计学意义(P<0.05)。结论:阿托伐他汀可显著提高冠心病患者的心功能,可能与其有效抑制炎症、氧化应激和降低血脂水平有关。
Objective: To investigate the clinical efficacy of atorvastatin in the treatment of coronary heart disease and its possible mechanism. Methods: 170 patients with coronary heart disease were divided into control group (n = 85) and study group (n = 85) according to the drawing method. The control group was treated routinely. The study group was treated with atorvastatin on the basis of control group Serum levels of inflammatory cytokines (TNF-α, MMP-9, CRP) and levels of oxidative stress (serum propylene glycol (MDA) (SOD), vascular endothelial function (serum nitric oxide (NO) and endothelin-1 (ET-1)), blood lipid and cardiac function. Results: After treatment, the levels of serum TNF-α, MMP-9, CRP, MDA, ET-1, total cholesterol (TC), triglyceride (TG), left ventricular end-diastolic dimension (LVEDD) (LVESD) levels were significantly lower than those in the control group, and serum SOD, NO and HDL-C LVEF levels were significantly higher than the control group, the difference was statistically significant ( P <0.05). Conclusion: Atorvastatin can significantly improve cardiac function in patients with coronary heart disease, which may be related to its effective inhibition of inflammation, oxidative stress and lowering of blood lipid levels.